Witepsol H15 è un grasso duro inerte utilizzato per rilascio di farmaci dalle supposte progesterone.
Le quantità normalmente utilizzate sono 1,1275 g per le supposte da 125 mg, 1,15 per medicamenti orali da 250 mg (1).
L'unico problema di questo grasso è la sua ossidazione se lasciato per lungo tempo in contatto con l'aria. Occorre quindi utilizzare in breve tempo i farmaci che lo contengono .
Studi
Aminolevulinic acid-loaded Witepsol microparticles manufactured using a spray congealing procedure: implications for topical photodynamic therapy. Al-Kassas R, Donnelly RF, McCarron PA. J Pharm Pharmacol. 2009 Sep;61(9):1125-35. doi: 10.1211/jpp/61.09.0001.
Preparation and in vitro-in vivo evaluation of Witepsol H35 based self-nanoemulsifying drug delivery systems (SNEDDS) of coenzyme Q(10).
Nepal PR, Han HK, Choi HK.
Eur J Pharm Sci. 2010 Feb 19;39(4):224-32. doi: 10.1016/j.ejps.2009.12.004.
Release property of progesterone from a mixed-base suppository consisting of Witepsol W35 and Witepsol E85. Iwata M, Komiya S, Nakamura K, Kiuchi M, Andoh N, Hirahara F, Maitani Y, Takayama K. Drug Dev Ind Pharm. 2001 Nov;27(10):1039-45.
Optimization of the production of solid Witepsol nanoparticles loaded with rosmarinic acid. Campos DA, Madureira AR, Gomes AM, Sarmento B, Pintado MM. Colloids Surf B Biointerfaces. 2014 Mar 1;115:109-17. doi: 10.1016/j.colsurfb.2013.10.035
Effect of different bile salts on the relative hypoglycemia of witepsol W35 suppositories containing insulin in diabetic Beagle dogs. Hosny EA, Al-Shora HI, Elmazar MM. Drug Dev Ind Pharm. 2001 Sep;27(8):837-45.
Investigation of diazepam lipospheres based on Witepsol and lecithin intended for oral or rectal delivery. Sznitowska M, Janicki S, Gajewska M, Kulik M. Acta Pol Pharm. 2000 Jan-Feb;57(1):61-4.
